CommentAssessing the benefits of triple versus dual fixed-dose combinations for the treatment of severe asthma
References (8)
- et al.
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial
Lancet
(2018) - et al.
Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials
Lancet
(2019) - et al.
Tiotropium in asthma poorly controlled with standard combination therapy
N Engl J Med
(2012) - et al.
Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT)
NPJ Prim Care Respir Med
(2016)
There are more references available in the full text version of this article.
Cited by (8)
Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications
2022, Allergy: European Journal of Allergy and Clinical ImmunologyEpidemiology of severe asthma and international register
2021, Minerva MedicaTriple therapy in uncontrolled asthma: A network meta-analysis of phase III studies
2021, European Respiratory Journal
© 2020 Elsevier Ltd. All rights reserved.